-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Upgrades Camp4 Therapeutics to Overweight, Raises Price Target to $9

Benzinga·06/16/2026 10:18:27
Listen to the news
JP Morgan analyst Anupam Rama upgrades Camp4 Therapeutics (NASDAQ:CAMP) from Neutral to Overweight and raises the price target from $5 to $9.